[Tolerability and Outcome of Neoadjuvant GS Therapy for Resectable Pancreatic Cancer].

Autor:	Yamashita M; Dept. of Surgery, Toyonaka Municipal Hospital., Shimizu J, Sato Y, Noma T, Hagihara K, Yanagimoto Y, Suzuki Y, Ikenaga M, Kawase T, Imamura H, Akagi K, Iwasawa S, Tomita N
Jazyk:	japonština
Zdroj:	Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2023 Dec; Vol. 50 (13), pp. 1411-1413.
Abstrakt:	Introduction: Neoadjuvant chemotherapy with gemcitabine plus S-1(NAC GS)has been reported to prolong the prognosis of resectable pancreatic cancer, and is now being used in daily practice. In this study, we investigated the tolerability and outcome of neoadjuvant GS therapy for resectable pancreatic cancer in our hospital. Patients: Fifty-two patients who underwent NAC GS for resectable pancreatic cancer between November 2019 and March 2023 were included in this study. Results: The mean age of all 52 patients was 75 years, 28 were male and 24 were female. Tumor site was pancreatic head cancer in 32 patients, pancreatic body cancer in 13 patients, and pancreatic tail cancer in 8 patients. Only 2 patients of the 52 patients completed 2 cycles of GS therapy with full dose, and dose reduction and treatment deferral were performed in remaining 50 patients. The dose intensity was 78.4% for gemcitabine and 66.7% for S-1. Grade 3 or higher adverse events included neutropenia in 21 patients(40.4%), biliary tract infection in 6 patients(11.5%), fatigue, anorexia, hepatic dysfunction, and constipation in 1 patient each(1.9%). 47 patients(90.4%)underwent R0 resection. 4 patients had pancreatic fistula, which was classified as Grade Ⅲ by Clavien-Dindo, and one of them died in the hospital due to bleeding from a pseudoaneurysm. Conclusion: NAC GS therapy for resectable pancreatic cancer was considered feasible with appropriate management of adverse events.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu